Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 4, 2023 4:05 PM EDTMultiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza
Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company through next phase of growth
 $2.3 billion in cash, cash equivalents, and investments as of March 31, 2023Â
SAN FRANCISCO, May 04, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2023.
Vir is at an exciting inflection... More
